

January 14, 2021

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Mothers)

Inquiries: Arihiko Bijohira, Executive Director & CFO

Phone: +81-3-6383-3746

License Agreement for anti-TROP-2 antibody development and commercialization

Chiome Bioscience Inc. (“Chiome”) announced today that Shanghai Henlius Biotech, Inc. (“Henlius”) has entered into Exclusive License Agreement with Chiome for development and commercialization of the anti-TPOR-2 antibodies, LIV-2008/2008b, generated by Chiome.

Under the Exclusive License Agreement, Chiome will grant an exclusive license, with sublicensing rights, to Henlius concerning development, manufacturing and marketing in China (including Hong Kong Special Administrative Region and Macau Special Administrative Region and Taiwan region) for LIV-2008/2008b. In addition, Chiome grants to Henlius option rights concerning development, manufacturing and marketing of LIV-2008/2008b in the rest of the world other than the initial territory, China (including Hong Kong Special Administrative Region and Macau Special Administrative Region and Taiwan region).

Chiome will receive 1 million USD as an upfront payment upon signing the Exclusive License Agreement. In case Henlius exercises the option rights as described above, the total value of the agreement which Henlius shall pay to Chiome will be 122.5 million USD. In addition, after the launch of LIV-2008/2008b or related products (Product), Chiome is eligible to receive royalties according to Henlius’s amount of sales of the Product.

Upon execution of this Agreement, the upfront payment shall be booked as sales of Drug Discovery and Development Business for the first quarter of the fiscal year ending December 31, 2021 and the impact on the business performance for this fiscal year is currently being considered.

<About Henlius>

Henlius is listed on the Stock Exchange of Hong Kong Limited (SEHK:2696) and is principally engaged in (i) the R&D, production and sale of monoclonal antibody (mAb) drugs and the provision of related technical services (except for the development and application of human stem cells, genetic diagnosis and therapy technology) and (ii) the transfer of its own technology and provision of the related technology consultation services.

<About LIV-2008/2008b>

LIV-2008/2008b are humanized monoclonal antibodies targeting cell surface antigen "TROP-2" (Trophoblast cell-surface antigen 2). TROP-2 is overexpressed in breast cancer, colon cancer, lung cancer and several types of solid cancers and also expected to play a key role in the proliferation of cancer cells. Chiome's R&D team discovered that the antibodies have shown potent anti-tumor activity in various in vivo mouse models and are expected to have beneficial clinical efficacy.